Bunavail® (buprenorphine/naloxone) – Expanded indication
April 27, 2017 – The FDA approved BioDelivery Sciences’ Bunavail (buprenorphine/naloxone) buccal film, for the treatment of opioid dependence as part of a complete treatment plan to include counseling and psychosocial support.
Download PDF
